Tags : Kyowa Hakko Kirin

AstraZeneca Signs Development and Commercialization Agreement with Kyowa Hakko Kirin

Shots: Kyowa Kirin to receives upfront, regulatory & commercial milestones. AstraZeneca to get global rights to develop & commercialize Fasenra (beralizumab) for all indication across 14 Asian countries including Japan In Mar,2017 AstraZeneca & Kyowa Kirin collaborated to develop & commercialize Fasenra (beralizumab) for severe asthma and chronic obstructive pulmonary disease (COPD) in Asia Fasenra […]Read More